Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Large Decrease in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 94,135 shares, a decrease of 36.2% from the April 30th total of 147,543 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 35,197 shares, the days-to-cover ratio is currently 2.7 days.

Estrella Immunopharma Trading Down 3.6%

NASDAQ:ESLA opened at $1.08 on Wednesday. The firm has a market capitalization of $46.47 million, a price-to-earnings ratio of -3.18 and a beta of 0.85. Estrella Immunopharma has a 1-year low of $0.78 and a 1-year high of $3.15. The business’s fifty day moving average price is $1.35 and its 200 day moving average price is $1.39.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. Equities analysts forecast that Estrella Immunopharma will post -0.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ESLA. Weiss Ratings lowered Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. D. Boral Capital restated a “buy” rating and issued a $8.00 price objective on shares of Estrella Immunopharma in a report on Monday, February 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in Estrella Immunopharma by 1,045.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares during the last quarter. Geode Capital Management LLC increased its position in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares during the last quarter. Marshall Wace LLP acquired a new position in Estrella Immunopharma in the 4th quarter worth about $88,000. XTX Topco Ltd increased its position in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the last quarter. Finally, State Street Corp increased its position in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares during the last quarter. 0.35% of the stock is owned by institutional investors and hedge funds.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.